IJAYUSH
International Journal of AYUSH
AYURVEDA • YOGA • UNANI • SIDDHA • HOMEOPATHY
https://internationaljournal.org.in/journal/index.php/ijayush/
ISSN: 2349-7025
OPEN ACCESS
★ PEER REVIEWED ★
MONTHLY

Review Article	Volume 15 Issue 07	July 2026

CONCEPTUAL REVIEW OF *VATARAKTA* WITH SPECIAL REFERENCE TO GOUT

***Dr. Sahil Mehla[1], Dr. Anand Pratap Singh[2], Dr. Nitin Goel[3]**

[1]P.G. Scholar, P.G. Dept. of Kayachikitsa, Kunwar Shekhar Vijendra Ayurved Medical College & Research Centre, Gangoh, Saharanpur – 247341

[2]Professor and HOD, P.G. Dept. of Kayachikitsa, Kunwar Shekhar Vijendra Ayurved Medical College & Research Centre, Gangoh, Saharanpur – 247341

[3]Assistant Professor, P.G. Dept. of Kayachikitsa, Kunwar Shekhar Vijendra Ayurved Medical College & Research Centre, Gangoh, Saharanpur – 247341

Corresponding Author - Dr. Sahil Mehla, P.G. Scholar, P.G. Dept. of Kayachikitsa, Kunwar Shekhar Vijendra Ayurved Medical College & Research Centre, Gangoh, Saharanpur – 247341

ABSTRACT

Background: Vatarakta is an important disease described in Ayurveda in which aggravated Vata and vitiated Rakta interact through reciprocal obstruction and aggravation, producing severe pain, swelling, discoloration, burning and functional limitation, often beginning in the distal joints. Gout is a crystal-induced inflammatory arthritis caused by deposition of monosodium urate crystals in and around joints. The marked involvement of the first metatarsophalangeal joint, episodic severe pain, erythema and swelling seen in gout provide a clinically useful basis for comparison with selected presentations of Vatarakta. A conceptual analysis can clarify convergent mechanisms while preserving the distinct diagnostic frameworks of Ayurveda and contemporary biomedicine. Aim To critically review the Ayurvedic concept of Vatarakta with special reference to the pathogenesis, clinical features and contemporary understanding of gout. Objectives To review the classical Ayurvedic description of Vatarakta under Nidana, Samprapti, Purvarupa, Rupa, Bheda and Chikitsa Siddhanta. To summarize the contemporary pathophysiology and characteristic clinical features of gout. To compare the Ayurvedic and biomedical disease models without assuming complete diagnostic identity. Materials and Methods: A narrative conceptual review was undertaken using major Ayurvedic classics and selected peer-reviewed biomedical literature on gout. Classical descriptions of Nidana, Samprapti, Rupa, Bheda and Chikitsa Siddhanta were synthesized. Gout pathophysiology, clinical features, classification and management principles were compared with the Ayurvedic framework. Results & Discussion: The Ayurvedic model emphasizes constitutional, dietary, metabolic and circulatory factors, whereas gout is defined by monosodium urate crystal deposition. Integrating both frameworks may improve conceptual understanding but does not

replace disease-specific diagnostic confirmation. Conclusion: Vatarakta provides a valuable Ayurvedic framework for understanding gout-like inflammatory arthritis. Careful correlation, rather than one-to-one equivalence, offers the most scientifically defensible approach.

Keywords: Vatarakta; Gout; Vata; Rakta; Hyperuricemia; Monosodium urate

INTRODUCTION

Gout is one of the most common forms of inflammatory arthritis and is produced by deposition of monosodium urate crystals after sustained urate supersaturation. The global burden has risen over recent decades, and contemporary estimates indicate substantial growth in the number of affected individuals as populations age and metabolic risk factors become more prevalent. Clinically, gout is characterized by recurrent attacks of intense joint pain, swelling, warmth and erythema, with the first metatarsophalangeal joint being a classic site; untreated disease may progress to tophi, chronic synovitis, erosive joint damage and disability.[1]

The biological basis of gout is now understood as a sequence beginning with hyperuricemia, followed by crystal formation and deposition, and then an innate immune response to those crystals. Renal and intestinal urate handling, genetic variation, diet, metabolic factors and medicines can influence serum urate. When monosodium urate crystals are present in joints, they can trigger a powerful inflammatory cascade involving the NLRP3 inflammasome and interleukin-1 beta, which explains the abrupt and severe nature of gout flares. This pathophysiological model has also established serum urate reduction as a central disease-modifying strategy.[2]

Ayurveda describes Vatarakta as a disorder arising from the interaction of aggravated Vata with vitiated Rakta. The disease is notable for pain, swelling, discoloration, burning, altered sensation and progressive involvement of joints and deeper tissues. Classical descriptions emphasize distal onset, particularly in the feet and hands, followed by extension when the disease becomes established. Because gout frequently presents with acute painful swelling of peripheral joints and may later become chronic and deforming, it is often discussed in Ayurvedic literature as an important modern clinical condition that can be interpreted through the framework of Vatarakta. The comparison is useful when treated as a conceptual correlation rather than an absolute equivalence.[3]

AIM AND OBJECTIVES

Aim

To critically review the Ayurvedic concept of Vatarakta with special reference to the pathogenesis, clinical features and contemporary understanding of gout.

Objectives

- To review the classical Ayurvedic description of *Vatarakta* under *Nidana*, *Samprapti*, *Purvarupa*, *Rupa*, *Bheda* and *Chikitsa Siddhanta*.
- To summarize the contemporary pathophysiology and characteristic clinical features of gout.

- To compare the Ayurvedic and biomedical disease models without assuming complete diagnostic identity.

MATERIALS AND METHODS

This narrative conceptual review was prepared by examining authoritative Ayurvedic texts dealing with Vatarakta and by reviewing selected biomedical literature on gout, including disease-burden analyses, gout classification criteria, pathophysiological studies and evidence-based management guidance. Information was organized into classical etiological factors, disease development, clinical manifestations, disease staging and management principles, followed by a structured comparison with the modern concept of gout. The review was interpretive rather than diagnostic: similarities were used to build conceptual bridges, while differences between the two medical systems were retained to avoid forced one-to-one equivalence.[4]

CONCEPTUAL STUDY

Vatarakta

The term Vatarakta denotes a pathological state in which aggravated Vata and vitiated Rakta become mutually involved. In the classical description, disturbed Rakta obstructs the normal movement of Vata, and the obstructed Vata in turn further disturbs Rakta. This reciprocal process produces a self-perpetuating pattern of pain, discoloration, swelling and tissue dysfunction. The disease is therefore not merely a local joint disorder; it reflects a systemic interaction involving Dosha, Dhatu and channels of transport. The prominence of pain points to Vata, while redness, heat, burning and altered blood-tissue behavior indicate significant participation of Rakta and, in many cases, Pitta.[5]

Nidana - Etiological Factors

The etiological framework of Vatarakta includes factors capable of vitiating either Rakta or Vata, together with habits that disturb both. Excessive intake of salty, sour, pungent, alkaline, very hot, heavy or incompatible foods can disturb Rakta and Pitta, while excessive dry, light, insufficient or irregular food intake, overexertion, fasting, trauma and other strain can aggravate Vata. Sedentary habits, daytime sleep, lack of physical activity, excessive indulgence and impaired digestion may contribute to metabolic disturbance and channel obstruction. The classical account therefore depicts Vatarakta as a disease in which dietary pattern, lifestyle, impaired digestion, tissue susceptibility and disturbed movement of Vata converge rather than acting as a single isolated cause.[6]

Samprapti - Pathogenesis

The core Samprapti begins when aggravated Vata encounters vitiated Rakta. Because Rakta occupies vascular and tissue channels, its abnormal state can impede normal Vata Gati, producing Margavarodha. Obstructed Vata becomes more forceful and further agitates Rakta, after which the combined disturbance circulates and localizes at vulnerable sites. Distal joints are particularly emphasized in classical descriptions, and repeated localization may produce recurrent painful episodes. With progression, the pathology can move from superficial tissues to deeper structures, reflecting increasing involvement of Mamsa, Meda, joints and other

supporting tissues. This sequence explains why early symptoms may be episodic and superficial whereas chronic disease can become persistent and structurally damaging.[7]

Purvarupa and *Rupa*

The symptom complex of Vatarakta includes severe pain, pricking or splitting sensations, throbbing, stiffness, swelling, itching, numbness, burning, redness or dusky discoloration and tenderness. Symptoms may fluctuate and can become aggravated by inappropriate food, exertion or other provoking factors. Peripheral involvement, especially of the feet and hands, is characteristic in many descriptions. These features create an obvious clinical resemblance to gout, where an acute flare often produces sudden severe pain, marked tenderness, swelling, warmth and erythema. The resemblance is strongest at the level of clinical expression; however, Ayurveda interprets these features through the dynamic relationship of Vata, Rakta, Pitta, Kapha and tissue channels rather than through crystal deposition alone.[8]

Bheda - *Uttana* and *Gambhira Vatarakta*

Vatarakta is classically differentiated into Uttana and Gambhira forms. Uttana Vatarakta predominantly affects more superficial tissues and commonly presents with itching, burning, pain, discoloration and relatively superficial swelling. Gambhira Vatarakta involves deeper tissues and is associated with more intense pain, deeper swelling, stiffness, hardness, functional restriction and chronic tissue involvement. This distinction is clinically important because it reflects depth and chronicity rather than only severity. In a gout correlation, recurrent acute inflammatory episodes may resemble superficial active disease, while longstanding tophaceous gout with deeper periarticular deposits, deformity and erosive change provides a more useful comparison with deeper and chronic manifestations.[9]

Dosha, Dushya, Srotas and *Adhishthana*

The principal Dosha is Vata, with essential participation of vitiated Rakta as the major affected Dhatu. Depending on presentation, Pitta may dominate when burning, redness, heat and rapid inflammation are prominent, while Kapha may contribute to heaviness, stiffness, persistent swelling or chronic thickening. Relevant Dushya can include Rakta, Mamsa, Meda and deeper joint-supporting tissues as the disease progresses. The involved pathways can be conceptually linked to Raktavaha Srotas and musculoskeletal channels, with joints acting as important sites of localization. This multi-factor formulation helps explain clinical heterogeneity: two patients with similar joint pain may express different patterns depending on the predominance of Vata, Pitta, Kapha, tissue depth and metabolic context.[10]

Role of *Margavarodha*, *Khavaigunya* and Distal Joint Predilection

A central interpretive feature in Vatarakta is obstruction of the physiological movement of Vata. When abnormal Rakta, metabolic products or tissue factors impede normal movement, the resulting Avarana and Margavarodha intensify pain and disturb local function. Localization occurs where tissue vulnerability or Khavaigunya is present. The classical preference for distal sites is striking because gout also frequently manifests first at peripheral joints, especially the first metatarsophalangeal joint. From a biomedical perspective, local temperature, urate concentration and tissue microenvironment influence crystal formation; from an Ayurvedic

perspective, such a distal predilection can be interpreted as a site-specific expression of altered Vata-Rakta dynamics and tissue susceptibility.[11]

Chikitsa Siddhanta

Management of Vatarakta is individualized according to Dosha dominance, disease depth, strength of the patient and associated metabolic disturbance. Classical principles include avoidance of causative factors, regulation of diet and lifestyle, appropriate Snehana and Swedana in selected states, Virechana, Basti, Raktamokshana where indicated, and local measures such as Parisheka, Pradeha or other applications according to the clinical pattern. The logic is to remove obstruction, normalize Vata Gati, pacify aggravated Rakta and associated Pitta, reduce pain and swelling, and prevent deeper tissue involvement. Because the condition can involve both obstructive and inflammatory components, treatment is not uniform; interventions suitable for one stage or Dosha pattern may be unsuitable for another.[12]

Biomedical Correlation with Gout

Gout is defined by deposition of monosodium urate crystals in articular or periarticular tissues, and crystal identification remains the most specific evidence of the disease. Modern classification incorporates clinical pattern, episodic time course, serum urate, crystal demonstration and characteristic imaging findings such as the ultrasound double-contour sign or urate deposition on dual-energy computed tomography. The intense pain, swelling, redness, warmth, recurrent attacks, distal joint preference and progression to chronic tissue deposits create meaningful parallels with Vatarakta. Nevertheless, hyperuricemia and crystal deposition are not classical Ayurvedic constructs, and not every patient with Vatarakta-like symptoms has gout. Therefore, the most rigorous position is that gout can represent one important bio medical condition that may be interpreted through a Vatarakta framework after appropriate clinical evaluation.[13]

Conceptual Correlation Between *Vatarakta* and Gout

Content	*Vatarakta*	Gout
Core mechanism	Aggravated *Vata* with vitiated *Rakta*; reciprocal aggravation and *Margavarodha*.	Urate supersaturation, monosodium urate crystal deposition and crystal-triggered inflammation.
Common site	Often begins in feet/hands and peripheral joints.	Frequently affects peripheral joints; first metatarsophalangeal joint is classic.
Pain	Severe *Ruk*, *Toda*, *Bheda*, throbbing or stiffness depending on *Dosha*.	Acute severe pain and exquisite tenderness during a flare.
Inflammation	*Shotha*, *Raga*, *Daha*, discoloration and tenderness.	Swelling, erythema, warmth and synovitis.
Course	Recurrent or progressive; may become deeper and chronic.	Intermittent flares can progress to chronic tophaceous and erosive disease.
Metabolic context	Diet, *Agni*, lifestyle, *Rakta* vitiation and channel obstruction are emphasized.	Hyperuricemia is the key biochemical substrate; renal/gut urate handling and metabolic risk are important.
Diagnostic anchor	Ayurvedic diagnosis based on *Nidana*, *Dosha-Dushya*, *Rupa*, stage and patient factors.	MSU crystal identification is definitive; validated clinical/laboratory/imaging criteria support classification.
Therapeutic aim	Normalize *Vata*, pacify *Rakta/Pitta*, remove obstruction, reduce inflammation and prevent deeper involvement.	Treat flares and lower serum urate sufficiently to dissolve crystals and prevent recurrence.

PROBABLE SAMPRAPTI OF VATARAKTA WITH GOUT CORRELATION

Predisposing *Nidana*: Dietary excess/irregularity, sedentary habits, metabolic disturbance, *Vata* aggravating factors and *Rakta* vitiating factors

↓

Disturbed *Agni* and metabolic handling: Formation/accumulation of pathological metabolic factors; in gout correlation, persistent hyperuricemia creates urate supersaturation

↓

Vitiation of *Rakta* + aggravation of *Vata*: Abnormal blood/tissue milieu with disturbed physiological movement

↓

Margavarodha and reciprocal aggravation: Vitiated *Rakta* obstructs *Vata*; aggravated *Vata* further disturbs *Rakta*

↓

Localization at *Khavaigunya*: Peripheral joints, especially feet and hands; in gout, MSU crystals deposit in susceptible articular/periarticular sites

↓

Acute inflammatory expression: Severe pain, tenderness, swelling, redness, warmth/burning, stiffness and functional limitation

↓

Recurrent/chronic disease: Repeated flares, deeper tissue involvement and structural change; gout may progress to tophi and erosive joint damage

PROBABLE SAMPRAPTI VIGHATANA

Avoidance of causative diet and lifestyle factors (*Nidana Parivarjana*)

↓

Correction of digestive-metabolic imbalance and reduction of obstructive factors

↓

Pacification of aggravated *Rakta/Pitta* and normalization of *Vata Gati*

↓

Reduction of pain, inflammation and joint dysfunction

↓

Prevention of recurrence and deeper tissue involvement

↓

In confirmed gout: biomedical urate-lowering and flare management according to standard clinical guidance

RESULTS AND FINDINGS

- *Vatarakta* is fundamentally described as a disorder of aggravated *Vata* interacting with vitiated *Rakta* through reciprocal obstruction and aggravation.
- Classical etiological factors include dietary, behavioral, metabolic and *Vata*-provoking influences rather than a single causative factor.

- The disease has a strong peripheral-joint orientation and commonly includes severe pain, swelling, redness/discoloration, burning, tenderness and stiffness.
- The distinction between *Uttana* and *Gambhira Vatarakta* reflects superficial versus deeper tissue involvement and provides a useful framework for understanding disease progression.
- Gout is a crystal-deposition disease in which sustained hyperuricemia promotes monosodium urate crystal formation and deposition.
- MSU crystals initiate intense innate immune inflammation, explaining the abrupt painful flare characteristic of gout.
- The first metatarsophalangeal joint and other peripheral joints are common gout sites, creating a strong clinical parallel with the distal distribution described in *Vatarakta*.
- The closest overlap between the two concepts is seen in acute painful swelling, erythema, warmth/burning, recurrence and progressive joint/tissue involvement.
- Hyperuricemia itself should not be equated with *Vatarakta* because many people with elevated serum urate do not have symptomatic gout, and *Vatarakta* has a broader Ayurvedic pathophysiological meaning.
- Likewise, *Vatarakta* should not automatically be diagnosed as gout without biomedical confirmation where gout is clinically suspected.
- A rigorous integrative interpretation uses Ayurvedic assessment for *Dosha*, *Dushya*, stage and causative factors while retaining crystal-based and serum-urate-based biomedical evaluation for gout.
- Long-term gout management requires control of the urate crystal burden in addition to relief of acute inflammation; this differs from treating only the presenting joint pain.
- The conceptual model of *Margavarodha*, tissue susceptibility and recurrent localization may offer a useful Ayurvedic lens for understanding why inflammatory episodes recur at vulnerable joints.
- The most defensible conclusion is a partial and clinically useful correlation rather than complete synonymy between *Vatarakta* and gout.

DISCUSSION

The classical Vatarakta model and the contemporary gout model converge most strongly at the level of inflammatory joint expression and recurrence. In Ayurveda, obstruction of Vata by vitiated Rakta and subsequent reciprocal aggravation provides the central explanation for severe pain, color change, burning, swelling and progressive tissue involvement. In gout, monosodium urate crystals act as a danger signal that activates innate immune pathways, including the NLRP3 inflammasome, leading to interleukin-1 beta production and a rapid neutrophil-rich inflammatory response. These models use different explanatory languages, but both recognize a predisposing internal milieu followed by localization at a susceptible joint and a disproportionate acute inflammatory reaction. The biomedical demonstration that urate crystals can directly initiate inflammasome-dependent inflammation provides a mechanistic counterpart to the Ayurvedic observation that a disturbed internal substrate can precipitate intense local disease.[14]

The therapeutic implications of the comparison are equally important. Acute symptom relief alone is insufficient for established gout because the underlying crystal burden persists unless serum urate is reduced below the saturation threshold. Current rheumatology guidance therefore emphasizes urate-lowering therapy for patients with indications such as tophaceous disease, radiographic damage or frequent flares, together with a treat-to-target approach and appropriate anti-inflammatory prophylaxis during urate-lowering initiation. In Ayurvedic terms, a comparable principle is that treatment should address both the manifested pain and swelling and the deeper factors that sustain Vata-Rakta disturbance, obstruction and recurrence. However, this similarity in therapeutic logic should not be used to replace evidence-based gout treatment; rather, it supports the broader principle that chronic recurrent disease requires correction of the sustaining pathophysiology, not only episodic suppression of symptoms.[15]

The strongest integrative position is therefore one of complementarity with diagnostic discipline. A patient presenting with sudden painful swelling of the great toe may fit classical features of Vatarakta, but contemporary assessment should also consider septic arthritis, calcium pyrophosphate deposition disease, trauma and other inflammatory arthritides. When gout is confirmed, serum urate reduction, patient education and long-term adherence are central to preventing crystal reaccumulation and future flares; randomized evidence has shown that structured, treat-to-target care can substantially improve urate control and clinical outcomes. Ayurveda can contribute a parallel individualized analysis of diet, lifestyle, Agni, Dosha dominance, tissue involvement and recurrence pattern. Future integrative research should therefore define reproducible Ayurvedic phenotypes within crystal-proven gout, use standardized outcome measures and clearly distinguish adjunctive Ayurvedic strategies from disease-modifying urate-lowering therapy.[16]

CONCLUSION

Vatarakta is a complex Ayurvedic disorder characterized by the interaction of aggravated Vata and vitiated Rakta, leading to Margavarodha, pain, swelling, discoloration, burning and progressive joint or tissue involvement. Gout shares several clinically important features, particularly recurrent severe inflammatory attacks in peripheral joints, but its defining biomedical basis is monosodium urate crystal deposition. The relationship between the two is therefore best understood as a strong clinical and conceptual correlation rather than exact equivalence. Integrative interpretation should preserve the diagnostic standards of gout while using the Ayurvedic framework to analyze causative factors, Dosha-Dushya involvement, disease stage and individualized therapeutic principles. This approach is more scientifically coherent and provides a stronger basis for future clinical research on Ayurvedic management in crystal-proven gout.

CONFLICT OF INTEREST - Nil.

SOURCE OF SUPPORT - None.

REFERENCES

1. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024;6(8):e507-e517.

2. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-1855.
3. Agnivesha. Charaka Samhita. Revised by Charaka and Dridhabala. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
4. Snyder H. Literature review as a research methodology: an overview and guidelines. J Bus Res. 2019;104:333-339.
5. Agnivesha. Charaka Samhita: Chikitsa Sthana, Vatarakta Chikitsa Adhyaya. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
6. Sushruta. Sushruta Samhita. Sharma PV, translator. Varanasi: Chaukhambha Visvabharati; 2013.
7. Vagbhata. Ashtanga Hridaya. Murthy KRS, translator. Varanasi: Chowkhamba Krishnadas Academy; 2018.
8. Madhavakara. Madhava Nidana (Roga Viniscaya). Murthy KRS, translator. Varanasi: Chaukhambha Orientalia; 2016.
9. Bhavamishra. Bhavaprakasha. Mishra BS, Vaishya R, editors. Varanasi: Chaukhambha Sanskrit Bhawan; 2018.
10. Govind Das Sen. Bhaisajya Ratnavali. Mishra S, editor. Varanasi: Chaukhambha Surbharati Prakashan; 2019.
11. Chakrapanidatta. Chakradatta. Sharma PV, translator. Varanasi: Chaukhambha Orientalia; 2007.
12. Yogaratnakara. Shastri L, editor. Varanasi: Chaukhambha Prakashan; 2017.
13. Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557-2568.
14. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241.
15. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760.
16. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403-1412.